Computer Design Leads To Cystic Fibrosis Drug Candidates | Chemical & Engineering News
Volume 90 Issue 18 | p. 35 | Concentrates
Issue Date: April 30, 2012

Computer Design Leads To Cystic Fibrosis Drug Candidates

Computer method based on custom-designed peptides that block protein binding interactions
Department: Science & Technology
News Channels: Biological SCENE
Keywords: cystic fibrosis, computational drug design

Starting with the structure of a protein related to cystic fibrosis, Duke University computational chemists have gone from theory to possible drug candidates for the disease (PLoS Comput. Biol., DOI: 10.1371/journal.pcbi.1002477). Cystic fibrosis is an inherited condition in which mucus builds up in the lungs and digestive tract, making it difficult to breathe and absorb food nutrients. The underlying cause is a defective gene that encodes a mutated version of the protein CFTR (cystic fibrosis transmembrane conductance regulator). The mutated protein misfolds, has impaired functionality, and is degraded abnormally fast; all three of those defects exacerbate disease symptoms. To reduce degradation, Bruce R. Donald of Duke University and coworkers used K*, a computational program they wrote, to design peptides capable of blocking binding between CFTR and CAL (CFTR-associated ligand), an interaction that promotes degradation. The predicted inhibitors bound CAL with high affinity and improved mutant CFTR function up to 12% in cultured cells from patients. Donald speculates that one of the inhibitors might work together with a different type of cystic fibrosis drug to boost CFTR activity in an additive way.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment